II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies
In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immun...
Saved in:
Published in | Einstein (São Paulo, Brazil) Vol. 15; no. 1; pp. 1 - 16 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English Portuguese |
Published |
Brazil
Instituto Israelita de Ensino e Pesquisa Albert Einstein
01.01.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Instructional Material/Guideline-2 ObjectType-Feature-3 content type line 23 Conflict of interest: none. |
ISSN: | 1679-4508 2317-6385 2317-6385 1679-4508 |
DOI: | 10.1590/S1679-45082017AE3844 |